Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TriGenix done in by a string of bad luck

Noteworthy

TriGenix done in by a string of bad luck

TriGenix Inc. is planning on closing its doors, a victim both of D. Blech's financial problems and the failure of Celtrix Pharmaceuticals Inc.'s Phase III BetaKine trial to show efficacy in macular holes.

TriGenix was launched in

Read the full 476 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE